Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc., a Delaware corporation and emerging growth company, on April 30, 2018. The report discloses a material change in the Company's executive leadership structure effective immediately on the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Departure: Gary Schuman resigned as Interim Chief Financial Officer effective April 30, 2018.
- Appointment: Kerri-Ann Millar was promoted from Controller to Vice President, Finance, succeeding Mr. Schuman as the Company's principal financial officer.
- Background: Ms. Millar joined the Company in September 2017. She previously served as Corporate Controller at Flexion Therapeutics, Inc. (2014-2017) and as a Finance Specialist at Curis, Inc. (2005-2014). She holds a BS in Accounting and Finance from Boston University and is a Certified Public Accountant.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the leadership transition.
Key Facts for Investor Verification
- Confirm the effective date of the CFO transition (April 30, 2018).
- Verify the new reporting structure with Kerri-Ann Millar as the principal financial officer.
- Review subsequent filings for any impact on financial reporting timelines or internal controls resulting from this leadership change.